ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

retatrutide

Also written as “Retatrutide”, “LY3437943” and “Retatrutide (LY3437943)”.

Its studies are mostly in Obesity · Diabetes Mellitus, Type 2 · Atherosclerosis · Non-alcoholic Fatty Liver Disease · Diabetes Mellitus, led by 2 companies.

Drug pageRetatrutide: every studyAll 33 studies of it, academic ones too, with its approvals, label and forms.
Furthest: phase 3, since May 22, 202333 company-led studies, 11 open or runningNext primary completion: Nov 2026 (phase 3)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Eli Lillyits history only3210 open or runningphase 3since May 22, 2023Feb 13, 2019Nov 2026phase 3 · NCT06662383
Hudson Biotech11 open or runningphase 2since Mar 8, 2026Mar 8, 2026Mar 14, 2027phase 2 · NCT07467447
  • Named in Eli Lilly’s own pipeline as Retatrutide, phase 3, as of Oct 29, 2026 (source).

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and studies of Hudson Biotech only; the figures above count every company.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). An open circle marks the day WHO proposed its name. Dates ahead are the sponsors’ estimates.

  1. Jan 19, 2023Named retatrutideINNProposed as its International Nonproprietary Name in WHO's List 128 · before, LY3437943
  2. Mar 8, 2026First study: phase 2 study in ObesityFirst studyNCT07467447 · 300 planned · China

Ahead

  1. Mar 14, 2027Primary completion: phase 2 study in ObesityNCT07467447

TargetBeta

“Glucagon receptor agonist; Glucagon-like peptide 1 receptor agonist; Gastric inhibitory polypeptide receptor agonist”ChEMBL 37, by rule

Other programs on the same three targets

ProgramCompanyFurthest phaseStudies
UBT251The United Laboratories Internationalphase 312
HRS-4729Jiangsu HengRui Medicinephase 25

Studies

The one study Hudson Biotech leads. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07467447Obesity · China2RecruitingMar 14, 2027300

How it is read

Names in the registry

  • “Retatrutide”, 18 entries
  • “LY3437943”, 14 entries
  • “Retatrutide (LY3437943)”, 1 entry
  • “[¹⁴C]-LY3437943”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.